Skip to main content
Dx & Vx Co., Ltd. logo

Dx & Vx Co., Ltd. — Investor Relations & Filings

Ticker · 180400 ISIN · KR7180400004 KO Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2021-03-08 Delisting Announcement
Country KR South Korea
Listing KO 180400

About Dx & Vx Co., Ltd.

https://www.dxvx.com/

Dx & Vx Co., Ltd. is a bio-healthcare company specializing in diagnostics and vaccine development. Its diagnostics division offers molecular diagnostic solutions, genomics and bioinformatics services, and customized companion diagnostics (CDx), leveraging an AI-based genome analysis platform. The company's therapeutic pipeline is centered on an innovative mRNA vaccine platform designed for long-term storage at room temperature. Key development areas include vaccines for infectious diseases, immuno-therapeutic cancer vaccines, oral treatments for obesity, and therapies for eye conditions. Additionally, Dx & Vx provides contract development, manufacturing, and sales organization (CDMO/CSO) services and commercializes microbiome-based products and health supplements.

Recent filings

Filing Released Lang Actions
기타시장안내(개선기간 종료에 따른 상장폐지여부 결정 안내)
Delisting Announcement Classification · 100% confidence The document is a short regulatory notice from the Korea Exchange regarding the status of a company's listing (Cancerrop). It details the expiration of an improvement period and the subsequent process for determining potential delisting. Since it is a regulatory announcement regarding listing status and does not fit into specific categories like 'Delisting Announcement' (which usually implies the final decision to delist) or 'Legal Proceedings', it is best classified as a general regulatory filing.
2021-03-08 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Cancerrop) announcing a significant change (over 30%) in revenue or profit structure. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) to inform investors of material financial changes before the full annual report is finalized. It provides key financial highlights and reasons for the variance, fitting the definition of an Earnings Release (ER) as it serves as an initial announcement of financial performance metrics. FY 2020
2021-01-29 Korean
[기재정정]주주명부폐쇄기간또는기준일설정
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming Annual General Meeting. It is a formal corporate announcement filed with a regulatory body (DART/KRX style). Since it does not fit into specific categories like dividend announcements or board changes, and is a standard regulatory disclosure, it falls under the RNS (Regulatory Filings) category.
2020-12-17 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain full financial statements or proxy materials, but rather serves as a formal notice of a corporate action. Given it is a regulatory announcement that does not fit into specific categories like dividend or share buyback, it falls under the general regulatory filing category.
2020-12-15 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for the company 'CancerRope'. It details the voting outcomes for specific agenda items, such as the re-election and dismissal of directors. According to the filing definitions, official results from shareholder votes at any general meeting (AGM or EGM) fall under the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category.
2020-12-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (임시주주총회 소집공고) issued by Cancerrop. It contains the meeting agenda, details on director appointments and removals, and management information required for shareholder review. This document is a standard proxy statement/information circular provided to shareholders to solicit votes for an upcoming meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2020-11-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.